Alzheimer’s Therapeutics Market
Alzheimer's Therapeutics Market By Drug Name (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine And Donepezil), Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Manufactured Combination) & Region - Forecast 2022 - 2032
Market Insights on Alzheimer's Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Alzheimer’s Therapeutics Market Outlook (2022-2032)
[363 Pages Report] The global Alzheimer’s therapeutics market is set to witness a valuation of US$ 2.8 Bn in 2022, and further expand at a CAGR of 9.3% to reach US$ 6.8 Bn by the year 2032. According to the recent study by Future Market Insights, Donepezil is leading the market by drug with a share of 68.4% in 2021 within the global market.
|
Data Points |
Market Insights |
|
Market Value 2021 |
US$ 2.6 Bn |
|
Market Value 2022 |
US$ 2.8 Bn |
|
Market Value 2032 |
US$ 6.8 Bn |
|
CAGR 2022-2032 |
9.3% |
|
Market Share of Top 5 Countries |
62.3% |
Alzheimer’s therapeutics holds approximately 2.4% of the overall US$ 109 Bn global target therapeutics market in 2021.
The global prevalence rate of Alzheimer’s is increasing because of factors like the increasing life expectancy, rise in the ageing population, and changes in lifestyles, among others. This will drive the Alzheimer’s therapeutics market in the coming years.
According to the World Health Organization (WHO), approximately 50 million individuals have Alzheimer’s disease in 2021, and there are nearly 10 million new cases recorded each year.
The total cost of Alzheimer's disease is increasing because of costly treatments and therapies which are being employed for Alzheimer’s disease management. According to the National Library of Medicine, it is projected that the cost of Alzheimer's disease to the global economy is set to increase from USD 818 billion in 2015 to USD 2 trillion by 2030.
To address this growing public health crisis, it is very important to identify the failure rate of various available drugs and treatments which are slowing down the progression of Alzheimer's disease.
Since the risk associated with drugs for Alzheimer's disease is high, biomarkers have emerged as key advancements, reducing the risk and enhancing therapeutic outcomes. Biomarkers are helping researchers identify key biological events regarding the disease and drugs that are being used in the treatment of Alzheimer's disease.
The use of biomarkers augments the drug development process by reducing risks related to drug development and adding value to the selection of the most optimal drug candidates for large and expensive phase 3 clinical trials. Because of this, the usage of biomarkers is increasing. With the development of novel biomarkers for therapeutic use, the market for Alzheimer’s disease is witnessing growth opportunities in terms of new drug therapy options.
Companies operating in the Alzheimer’s therapeutics market are actively seeking to strengthen their position through acquisitions and mergers, which significantly accelerate the manufacturer’s ability to capture a significant share of the market.
For instance:
- On April 5 2021, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. Through this acquisition, Amneal gained the pipeline of 505(b)2 branded products and complex generics.
The global Alzheimer’s therapeutics market is expected to record sales worth US$ 2.8 Bn in the year 2022 and is set to expand at a CAGR of 9.3% over the forecast period (2022-2032).
Sales Analysis of Alzheimer’s Therapeutics from 2017 to 2021 Vs Market Outlook for 2022 to 2032
The sale of Alzheimer’s therapeutics expanded at a CAGR of 6.5% from 2017 to 2021 owing to the increased adoption of generic drugs like Donepezil by people, increasing use of biomarkers in Alzheimer’s diagnosis and drug development.
Many research activities regarding the development of diagnostic technologies are ongoing in the world for the treatment of Alzheimer’s. In addition to the traditional treatment therapies, new technologies are assisting in the diagnosis and treatment of Alzheimer's disease. New diagnostic criteria are helping to identify the validated diagnostic biomarkers. Increasing healthcare awareness and new diagnostic technologies for Alzheimer’s disease are fuelling the growth of the global Alzheimer’s disease therapeutics market in the forecast period.
According to the National Institute of Aging, researchers have identified more than 25 genes, which are additional genes involved in Alzheimer's disease and play a role in the treatment of the disease. By finding out these pathways, researchers are identifying possible targets for drugs and non-drug interventions to stop or prevent the disease.
For instance, genes involved in the treatment of inflammation have recently been found to be associated with Alzheimer’s and can serve as therapeutic targets in the near future.
Many new technologies are being used to monitor Alzheimer's disease and to detect its progression over time, which guides individuals in maintaining and tracking their activities. Increasing R&D spending and ongoing development of new therapies to treat, delay, and prevent the disease, as well as early diagnosis of the condition is creating an array of opportunities in the market for Alzheimer’s Therapeutics.
Thus, offers a great opportunity for the manufacturers of the industry to grow at a CAGR of 9.3% from 2022 to 2032 globally.
Let us know your requirement to get
100% FREE customization
What are the Key Opportunities for Alzheimer’s Therapeutics Kits Manufacturers?
In terms of Alzheimer’s, there has been an increase in the applications of various machine learning approaches, most commonly with imaging data for diagnosis and disease progression. This includes amyloid PET imaging, combined PET and MR imaging, and spectral phenotyping, among others.
For example, researchers from VA Bedford and VA Boston healthcare systems developed a non-invasive optical technique that helps detect the condition of Alzheimer’s disease. This new technique uses spectroscopy to identify structural changes in the brain.
This technological advancement has evolved to address the needs of people with dementia, informal caregivers, formal caregivers and social caregivers, and created a huge opportunity in the Alzheimer’s therapeutics market.
In terms of the impact of the aduhelm drug, the pressure has increased on the government-funded health programs such as Medicare for the elder population and Medicaid for low-income families, as millions of Americans lost their employer-sponsored health insurance. Medicare is expected to be hit the hardest since most Alzheimer's patients are over 65 years of age.
The expected budget for Alzheimer’s therapeutics is to be double as compared to the budget for all other physician-administered drugs. Furthermore, payment for expensive brain scans associated with a diagnosis of Alzheimer's payment is still not clear. coverage policy, when it emerges, could necessarily limit treatment usage - and private insurers are likely to follow suit. Thus the drug is expected to increase insurance premiums and increase out of pocket costs.
All the above scenarios offer a great opportunity for market growth during the forecast period from 2022 to 2032.
What are the Factors Restraining Demand for Alzheimer’s Therapeutics?
Many Alzheimer’s therapies have been discontinued in recent years, such as drugs like donepezil and others. According to the National Library of Medicine, in 2021, donepezil showed adverse effects on the patients, which is the primary reason for its discontinuation.
This rate of discontinuation is increasing because of the lack of improvement in cognitive function, very less efficacy on Alzheimer's disease symptomatology and the lack of a reliable safety profile of the drugs used in the treatment. This factor is contributing to the high discontinuation rates of current therapies due to their side effects, which is restraining the growth of the Alzheimer’s therapeutics market during the forecast period.
Stigma associated with Alzheimer’s disease remains a major barrier in the diagnosis and overall prognosis of Alzheimer’s disease. Self-stigma and societal stigma are hampering the diagnosis pathway.
In some regions, there are false beliefs regarding the treatment and diagnosis of Alzheimer’s, which is adding fuel to the stigma. Delay in seeking help is also one of the factors causing a delay in the treatment and diagnosis of the disease which is one of the major factor to hamper the market growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystCountry-wise Insights
What Makes the U.S. the Largest Market for Alzheimer’s Therapeutics?
The U.S. rules the North American region with a total market share of about 93.4% in 2021 and is expected to experience the same growth throughout the forecast period. The U.S. is the most lucrative market for Alzheimer’s therapeutics owing to the rise in prevalence of Alzheimer’s disease and other types of dementia in the region as well as a huge investment in research and development activities, and the launch of new products in the region.
For instance, according to the Journal of the Alzheimer’s Association, In the U.S., About 1 in 9 people which comprised 10.7% of the people aged 65 and older are having Alzheimer’s dementia. approximately, 5.0% of the population aged 65-74, 13.1% of the population aged 75-84, and 33.2% of the population aged 85 and older have Alzheimer’s dementia.
Why Germany is considered a Lucrative Market for Alzheimer’s therapeutics in Europe?
Germany is set to exhibit a CAGR of nearly 21.6% in the European Alzheimer’s therapeutics market during the forecast period owing to an increase in the elderly population, an escalation in healthcare expenditure, and increasing funding from the government.
According to the Journal of the Alzheimer’s Association, In Germany, about more than 1.5 million people are living presently with Alzheimer’s disease.
Additionally, increasing life expectancy in Germany and other parts of Europe boosts the market to grow forward during the forecast period from 2022 to 2032 in the region.
What Makes China an Emerging Market for Alzheimer’s Therapeutics?
China holds a 41.2% share in the East Asia Alzheimer’s therapeutics market in 2021 and is projected to increase at a high CAGR rate of 12.2% during the forecast period. This growth is associated with rapidly improving medical infrastructure, increasing scientific studies associated with the treatment and monitoring of Alzheimer's disease, as well as significant government and private sector funding in the country's Alzheimer's research is driving the market growth during the forecast years in China.
Category-wise Insights
Which Alzheimer’s therapeutics drug is driving market growth?
Donepezil project lucrative growth at a CAGR of 9.2% till the end of the forecast period, with a market share of around 68.4% in 2021. The administration of donepezil improves the cognitive function in patients for up to 52 weeks with Alzheimer’s disease without increasing the risk of clinically significant safety events, which makes it the most lucrative drug in all the drugs of Alzheimer’s disease.
Which Drug class is Large of Focus in the Alzheimer’s Therapeutics Market?
Cholinesterase Inhibitors hold a revenue share of 90.9% in 2021 and are expected to hold a similar share over the forecast period at a CAGR of 9.2% in 2021.
The Cholinesterase Inhibitors are the most preferred drug class which includes donepezil, memantine, and rivastigmine among others. Cholinesterase inhibitors functions in the peripheral nervous system and the central nervous system associated with the disease and work as the most effective treatment.
This factor makes it the most preferred drug class and thus it is expected to boost the market during the forecast period from 2022 to 2032.
Which Distribution Channel Benefits the Most by Employment of Alzheimer’s Therapeutics?
Hospitals are the leading segment in the Alzheimer’s therapeutics market with a 33.8% market share in 2021 and are expected to hold a similar share over the forecast period growing at a CAGR of 10.5% in 2021 due to the easy access and availability of drugs and therapies for Alzheimer’s treatment.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Competitive Landscape
Key players in the Alzheimer’s therapeutics market are actively focusing on collaboration, product launch, and expansion to gain a strong position in the market.
These strategies will help market players to enhance their product portfolio together with market penetration. Thereby, increasing their overall revenue share in the global Alzheimer’s therapeutics market.
Given below are a few examples of the key strategies followed by the manufacturers:
- March 2019, Zydus Cadila received US FDA approval to market its Rivastigmine transdermal system, used in the treatment of Alzheimer's disease
- In September 2017, Zydus received approval from U.S. FDA for Donepezil hydrochloride tablets which are used for the treatment of dementia of the Alzheimer’s type.
- In March 2022, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer’s disease
Similarly, recent developments related to companies manufacturing Alzheimer’s therapeutics products have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope as per Alzheimer’s Therapeutics Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2017-2021 |
|
Historical Data Available for |
2022-2032 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa |
|
Key Countries Covered |
US, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, U.K., Spain, BENELUX, Nordic countries, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Philippines, Indonesia, Vietnam, Australia, New Zealand, GCC countries, Israel, Turkey, South Africa and North Africa. |
|
Key Market Segments Covered |
Drug Name, Drug Class, Distribution Channel and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered in Alzheimer’s Therapeutics Industry Research
By Drug Name:
- Donepezil
- Rivastigmine
- Memantine
- Galantamine
- Manufactured combination of memantine and donepezil
By Drug Class:
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Manufactured Combination
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Frequently Asked Questions
The global Alzheimer’s therapeutics market is worth US$ 2.6 Bn in 2021 and is set to expand 2.4X over the next ten years.
From 2017-2021, the market for Alzheimer’s therapeutics expanded at the rate of 6.5%, owing to an increasing pool of Alzheimer’s patients across the globe.
The Alzheimer’s therapeutics market is expected to reach US$ 6.8 Bn by the end of 2032, with sales revenue expected to register a CAGR of 9.3%.
The U.S., Germany, U.K., China and France are the top five countries that are expected to drive demand for the Alzheimer’s therapeutics industry.
North America is one of the key markets for Alzheimer’s therapeutics, with the U.S. expected to account for nearly 93.4% of the North American market in the year 2021.
At what percentage is the demand for Alzheimer’s Therapeutics expected to register growth in Europe?
Demand for Alzheimer’s therapeutics in Europe is expected to register a growth of 9.3% over the next ten years.
The U.S., Germany and U.K. are key producers of Alzheimer’s therapeutics products.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Treatment Regime
4.2. Disease epidemiology of Alzheimer’s disease
4.3. Product Adoption/ Usage Analysis, by region
4.4. Recent Product Approval
4.5. Key Promotional Strategies by Market Players
4.6. Regulatory Scenario
4.7. Pipeline Assessment
4.8. Porter’s Analysis
4.9. PESTLE Analysis
4.10. Supply Chain Analysis
4.11. Dosage Patterns
4.12. Impact of Aduhelm Drug
5. Global Alzheimer’s Therapeutics Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
5.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
5.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global Healthcare Spending Overview
6.1.2. Global Pharmaceutical Market Outlook
6.1.3. Global Prevalence of Dementia
6.2. Forecast Factors - Relevance & Impact
6.2.1. Rising ageing population
6.2.2. Growing investment in healthcare expenditure
6.2.3. Growing advancements in diagnostic technologies
6.2.4. Rising prevalence of neurodegenerative disease
6.2.5. Adverse effects may impact the market growth
6.2.6. Key Strategic Developments
6.2.7. Product Adoption Rate and Demand
6.2.8. New Product Launches
6.3. COVID-19 Crisis – Impact Assessment
6.3.1. COVID-19 Crisis Analysis
6.3.2. Current GDP Projection and Probable Impact
6.3.3. Short-Mid-Long Term Outlook
6.3.4. Impact of COVID-19 on caregivers of Alzheimer’s disease
6.3.5. Impact of COVID-19 on Alzheimer’s disease diagnosis
6.4. Market Dynamics
6.4.1. Drivers
6.4.2. Restraints
6.4.3. Opportunity Analysis
6.5. Global Supply Demand Analysis
7. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis, By Drug Name, 2017–2021
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Name, 2022–2032
7.3.1. Donepezil
7.3.2. Rivastigmine
7.3.3. Memantine
7.3.4. Galantamine
7.3.5. Manufactured Combination of memantine and donepezil
7.4. Market Attractiveness Analysis, By Drug Name
8. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2017–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2022–2032
8.3.1. Cholinesterase Inhibitors
8.3.2. NMDA Receptor Antagonists
8.3.3. Manufactured Combination
8.4. Market Attractiveness Analysis, By Drug Class
9. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2017–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2022–2032
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Drug Stores
9.3.4. Online Pharmacies
9.4. Market Attractiveness Analysis, By Distribution Channel
10. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis, By Region, 2017–2021
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2022–2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis, By Region
11. North America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
11.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug Name
11.3.3. By Drug Class
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Drug Name
11.4.3. By Drug Class
11.4.4. By Distribution Channel
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
11.7. Country Level Analysis & Forecast
11.7.1. U.S. Alzheimer’s Therapeutics Market Analysis
11.7.1.1. Introduction
11.7.1.2. Market Analysis and Forecast, By Market Taxonomy
11.7.1.2.1. By Drug Name
11.7.1.2.2. By Drug Class
11.7.1.2.3. By Distribution Channel
11.7.2. Canada Alzheimer’s Therapeutics Market Analysis
11.7.2.1. Introduction
11.7.2.2. Market Analysis and Forecast, By Market Taxonomy
11.7.2.2.1. By Drug Name
11.7.2.2.2. By Drug Class
11.7.2.2.3. By Distribution Channel
12. Latin America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
12.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. Mexico
12.3.1.2. Brazil
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Name
12.3.3. By Drug Class
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Name
12.4.3. By Drug Class
12.4.4. By Distribution Channel
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
12.7. Country Level Analysis & Forecast
12.7.1. Mexico Alzheimer’s Therapeutics Market Analysis
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast, By Market Taxonomy
12.7.1.2.1. By Drug Name
12.7.1.2.2. By Drug Class
12.7.1.2.3. By Distribution Channel
12.7.2. Brazil Alzheimer’s Therapeutics Market Analysis
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast, By Market Taxonomy
12.7.2.2.1. By Drug Name
12.7.2.2.2. By Drug Class
12.7.2.2.3. By Distribution Channel
12.7.3. Argentina Alzheimer’s Therapeutics Market Analysis
12.7.3.1. Introduction
12.7.3.2. Market Analysis and Forecast, By Market Taxonomy
12.7.3.2.1. By Drug Name
12.7.3.2.2. By Drug Class
12.7.3.2.3. By Distribution Channel
13. Europe Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
13.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Nordic Countries
13.3.1.8. Russia
13.3.1.9. Rest of Europe
13.3.2. By Country
13.3.3. By Drug Name
13.3.4. By Drug Class
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Name
13.4.3. By Drug Class
13.4.4. By Distribution Channel
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. Germany Alzheimer’s Therapeutics Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast, By Market Taxonomy
13.7.1.2.1. By Drug Name
13.7.1.2.2. By Drug Class
13.7.1.2.3. By Distribution Channel
13.7.2. Italy Alzheimer’s Therapeutics Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast, By Market Taxonomy
13.7.2.2.1. By Drug Name
13.7.2.2.2. By Drug Class
13.7.2.2.3. By Distribution Channel
13.7.3. France Alzheimer’s Therapeutics Market Analysis
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast, By Market Taxonomy
13.7.3.2.1. By Drug Name
13.7.3.2.2. By Drug Class
13.7.3.2.3. By Distribution Channel
13.7.4. U.K. Alzheimer’s Therapeutics Market Analysis
13.7.4.1. Introduction
13.7.4.2. Market Analysis and Forecast, By Market Taxonomy
13.7.4.2.1. By Drug Name
13.7.4.2.2. By Drug Class
13.7.4.2.3. By Distribution Channel
13.7.5. Spain Alzheimer’s Therapeutics Market Analysis
13.7.5.1. Introduction
13.7.5.2. Market Analysis and Forecast, By Market Taxonomy
13.7.5.2.1. By Drug Name
13.7.5.2.2. By Drug Class
13.7.5.2.3. By Distribution Channel
13.7.6. BENELUX Alzheimer’s Therapeutics Market Analysis
13.7.6.1. Introduction
13.7.6.2. Market Analysis and Forecast, By Market Taxonomy
13.7.6.2.1. By Drug Name
13.7.6.2.2. By Drug Class
13.7.6.2.3. By Distribution Channel
13.7.7. Nordic Countries Alzheimer’s Therapeutics Market Analysis
13.7.7.1. Introduction
13.7.7.2. Market Analysis and Forecast, By Market Taxonomy
13.7.7.2.1. By Drug Name
13.7.7.2.2. By Drug Class
13.7.7.2.3. By Distribution Channel
13.7.8. Russia Alzheimer’s Therapeutics Market Analysis
13.7.8.1. Introduction
13.7.8.2. Market Analysis and Forecast, By Market Taxonomy
13.7.8.2.1. By Drug Name
13.7.8.2.2. By Drug Class
13.7.8.2.3. By Distribution Channel
14. East Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
14.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Country
14.3.3. By Drug Name
14.3.4. By Drug Class
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Name
14.4.3. By Drug Class
14.4.4. By Distribution Channel
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. China Alzheimer’s Therapeutics Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast, By Market Taxonomy
14.7.1.2.1. By Drug Name
14.7.1.2.2. By Drug Class
14.7.1.2.3. By Distribution Channel
14.7.2. Japan Alzheimer’s Therapeutics Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast, By Market Taxonomy
14.7.2.2.1. By Drug Name
14.7.2.2.2. By Drug Class
14.7.2.2.3. By Distribution Channel
14.7.3. South Korea Alzheimer’s Therapeutics Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast, By Market Taxonomy
14.7.3.2.1. By Drug Name
14.7.3.2.2. By Drug Class
14.7.3.2.3. By Distribution Channel
15. South Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
15.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Malaysia
15.3.1.4. Philippines
15.3.1.5. Indonesia
15.3.1.6. Vietnam
15.3.1.7. Rest of South Asia
15.3.2. By Drug Name
15.3.3. By Drug Class
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Name
15.4.3. By Drug Class
15.4.4. By Distribution Channel
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. India Alzheimer’s Therapeutics Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast, By Market Taxonomy
15.7.1.2.1. By Drug Name
15.7.1.2.2. By Drug Class
15.7.1.2.3. By Distribution Channel
15.7.2. Thailand Alzheimer’s Therapeutics Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast, By Market Taxonomy
15.7.2.2.1. By Drug Name
15.7.2.2.2. By Drug Class
15.7.2.2.3. By Distribution Channel
15.7.3. Malaysia Alzheimer’s Therapeutics Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast, By Market Taxonomy
15.7.3.2.1. By Drug Name
15.7.3.2.2. By Drug Class
15.7.3.2.3. By Distribution Channel
15.7.4. Philippines Alzheimer’s Therapeutics Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast, By Market Taxonomy
15.7.4.2.1. By Drug Name
15.7.4.2.2. By Drug Class
15.7.4.2.3. By Distribution Channel
15.7.5. Indonesia Alzheimer’s Therapeutics Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast, By Market Taxonomy
15.7.5.2.1. By Drug Name
15.7.5.2.2. By Drug Class
15.7.5.2.3. By Distribution Channel
15.7.6. Vietnam Alzheimer’s Therapeutics Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast, By Market Taxonomy
15.7.6.2.1. By Drug Name
15.7.6.2.2. By Drug Class
15.7.6.2.3. By Distribution Channel
15.7.7. Rest of South Asia Alzheimer’s Therapeutics Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast, By Market Taxonomy
15.7.7.2.1. By Drug Name
15.7.7.2.2. By Drug Class
15.7.7.2.3. By Distribution Channel
16. Oceania Alzheimer’s Therapeutics Market 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
16.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.2. Australia
16.3.3. New Zealand
16.3.4. By Drug Name
16.3.5. By Drug Class
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Name
16.4.3. By Drug Class
16.4.4. By Distribution Channel
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. Australia Alzheimer’s Therapeutics Market Analysis
16.7.2.Introduction
16.7.3. Market Analysis and Forecast, By Market Taxonomy
16.7.3.1. By Drug Name
16.7.3.2.By Drug Class
16.7.3.3. By Distribution Channel
16.7.2. New Zealand Alzheimer’s Therapeutics Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast, By Market Taxonomy
16.7.2.2.1. By Drug Name
16.7.2.2.2. By Drug Class
16.7.2.2.3. By Distribution Channel
17. Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
17.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Israel
17.3.1.3. Turkey
17.3.1.4. South Africa
17.3.1.5. North Africa
17.3.1.6. Rest of Middle East and Africa
17.3.2. By Drug Name
17.3.3. By Drug Class
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Name
17.4.3. By Drug Class
17.4.4. By Distribution Channel
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. GCC Countries Alzheimer’s Therapeutics Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast, By Market Taxonomy
17.7.1.2.1. By Drug Name
17.7.1.2.2. By Drug Class
17.7.1.2.3. By Distribution Channel
17.7.2. Israel Alzheimer’s Therapeutics Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast, By Market Taxonomy
17.7.2.2.1. By Drug Name
17.7.2.2.2. By Drug Class
17.7.2.2.3. By Distribution Channel
17.7.3. Turkey Alzheimer’s Therapeutics Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast, By Market Taxonomy
17.7.3.2.1. By Drug Name
17.7.3.2.2. By Drug Class
17.7.3.2.3. By Distribution Channel
17.7.4. South Africa Alzheimer’s Therapeutics Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast, By Market Taxonomy
17.7.4.2.1. By Drug Name
17.7.4.2.2. By Drug Class
17.7.4.2.3. By Distribution Channel
17.7.5. North Africa Alzheimer’s Therapeutics Market Analysis
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast, By Market Taxonomy
17.7.5.2.1. By Drug Name
17.7.5.2.2. By Drug Class
17.7.5.2.3. By Distribution Channel
17.7.6. Rest of MEA Alzheimer’s Therapeutics Market Analysis
17.7.6.1. Introduction
17.7.6.2. Market Analysis and Forecast, By Market Taxonomy
17.7.6.2.1. By Drug Name
17.7.6.2.2. By Drug Class
17.7.6.2.3. By Distribution Channel
18. Market Structure Analysis
18.1. Market Analysis, By Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis
19. Competition Analysis
19.1. Competition Dashboard
19.2. Key Development Analysis
19.3. Competition Benchmarking
19.4. Competition Deep Dive
19.4.1. Biogen Inc.
19.4.1.1. Overview
19.4.1.2. Product Portfolio
19.4.1.3. Profitability by Market Segments (Product/Channel/Region)
19.4.1.4. Sales Footprint
19.4.1.5. Strategy Overview
19.4.2. AbbVie, Inc.
19.4.2.1. Overview
19.4.2.2. Product Portfolio
19.4.2.3. Profitability by Market Segments (Product/Channel/Region)
19.4.2.4. Sales Footprint
19.4.2.5. Strategy Overview
19.4.3. Teva Pharmaceuticals Ltd.
19.4.3.1. Overview
19.4.3.2. Product Portfolio
19.4.3.3. Profitability by Market Segments (Product/Channel/Region)
19.4.3.4. Sales Footprint
19.4.3.5. Strategy Overview
19.4.4. Eisai Co., Ltd.
19.4.4.1. Overview
19.4.4.2. Product Portfolio
19.4.4.3. Profitability by Market Segments (Product/Channel/Region)
19.4.4.4. Sales Footprint
19.4.4.5. Strategy Overview
19.4.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
19.4.5.1. Overview
19.4.5.2. Product Portfolio
19.4.5.3. Profitability by Market Segments (Product/Channel/Region)
19.4.5.4. Sales Footprint
19.4.5.5. Strategy Overview
19.4.6. Novartis AG
19.4.6.1. Overview
19.4.6.2. Product Portfolio
19.4.6.3. Profitability by Market Segments (Product/Channel/Region)
19.4.6.4. Sales Footprint
19.4.6.5. Strategy Overview
19.4.7. Zydus Lifesciences Ltd (CADILA)
19.4.7.1. Overview
19.4.7.2. Product Portfolio
19.4.7.3. Profitability by Market Segments (Product/Channel/Region)
19.4.7.4. Sales Footprint
19.4.7.5. Strategy Overview
19.4.8. Sun Pharmaceutical Industries Ltd.
19.4.8.1. Overview
19.4.8.2. Product Portfolio
19.4.8.3. Profitability by Market Segments (Product/Channel/Region)
19.4.8.4. Sales Footprint
19.4.8.5. Strategy Overview
19.4.9. Dr. Reddy's Laboratories Ltd
19.4.9.1. Overview
19.4.9.2. Product Portfolio
19.4.9.3. Profitability by Market Segments (Product/Channel/Region)
19.4.9.4. Sales Footprint
19.4.9.5. Strategy Overview
19.4.10. Aurobindo Pharma Ltd
19.4.10.1. Overview
19.4.10.2. Product Portfolio
19.4.10.3. Profitability by Market Segments (Product/Channel/Region)
19.4.10.4. Sales Footprint
19.4.10.5. Strategy Overview
19.4.11. Amneal Pharmaceuticals Inc.
19.4.11.1. Overview
19.4.11.2. Product Portfolio
19.4.11.3. Profitability by Market Segments (Product/Channel/Region)
19.4.11.4. Sales Footprint
19.4.11.5. Strategy Overview
19.4.12. Macleods Pharmaceuticals Ltd.
19.4.12.1. Overview
19.4.12.2. Product Portfolio
19.4.12.3. Profitability by Market Segments (Product/Channel/Region)
19.4.12.4. Sales Footprint
19.4.12.5. Strategy Overview
19.4.13. Viatris Inc.
19.4.13.1. Overview
19.4.13.2. Product Portfolio
19.4.13.3. Profitability by Market Segments (Product/Channel/Region)
19.4.13.4. Sales Footprint
19.4.13.5. Strategy Overview
19.4.14. Lupin Ltd
19.4.14.1. Overview
19.4.14.2. Product Portfolio
19.4.14.3. Profitability by Market Segments (Product/Channel/Region)
19.4.14.4. Sales Footprint
19.4.14.5. Strategy Overview
19.4.15. Cipla Ltd.
19.4.15.1. Overview
19.4.15.2. Product Portfolio
19.4.15.3. Profitability by Market Segments (Product/Channel/Region)
19.4.15.4. Sales Footprint
19.4.15.5. Strategy Overview
19.4.16. Torrent pharmaceuticals ltd.
19.4.16.1. Overview
19.4.16.2. Product Portfolio
19.4.16.3. Profitability by Market Segments (Product/Channel/Region)
19.4.16.4. Sales Footprint
19.4.16.5. Strategy Overview
19.4.17. Unichem laboratories ltd
19.4.17.1. Overview
19.4.17.2. Product Portfolio
19.4.17.3. Profitability by Market Segments (Product/Channel/Region)
19.4.17.4. Sales Footprint
19.4.17.5. Strategy Overview
19.4.18. Lannett Inc.
19.4.18.1. Overview
19.4.18.2. Product Portfolio
19.4.18.3. Profitability by Market Segments (Product/Channel/Region)
19.4.18.4. Sales Footprint
19.4.18.5. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology
Let us know your requirement to get
100% FREE customization
Table 01: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 02: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 03: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Table 04: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Region
Table 05: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 06: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 07: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 08: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Table 09: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 10: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 11: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 12: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Table 13: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 14: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 15: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 16: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Table 17: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 18: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 19: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 20: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Table 21: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 22: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 23: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 24: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Table 25: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 26: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 27: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 28: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Table 29: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country
Table 30: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
Table 31: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class
Table 32: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFigure 01: Global Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 02: Global Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 03: Global Alzheimer’s Therapeutics Market Absolute $ Opportunity, 2021–2032
Figure 04: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Drug Name, 2022 & 2032
Figure 05: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Drug Name, 2022–2032
Figure 06: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 07: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Drug Class, 2022 & 2032
Figure 08: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Drug Class, 2022–2032
Figure 09: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 10: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Distribution Channel, 2022 & 2032
Figure 11: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Distribution Channel, 2022–2032
Figure 12: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 13: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Region, 2022 & 2032
Figure 14: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Region, 2022–2032
Figure 15: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Region, 2022–2032
Figure 16: North America Alzheimer’s Therapeutics Market Split By Country, 2022 (E)
Figure 17: North America Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)
Figure 18: North America Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)
Figure 19: North America Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)
Figure 20: North America Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 21: North America Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 22: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 23: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 24: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 25: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032
Figure 26: U.S Market Value Proportion Analysis, 2022
Figure 27: Global Vs. U.S Growth Comparison, 2022-2032
Figure 28: U.S. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 29: U.S. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 30: U.S. Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 31: Canada Market Value Proportion Analysis, 2022
Figure 32: Global Vs. Canada Growth Comparison, 2022-2032
Figure 33: Canada Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 34: Canada Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 35: Canada Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 36: Latin America Alzheimer’s Therapeutics Market Split By Country, 2022 (E)
Figure 37: Latin America Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)
Figure 38: Latin America Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)
Figure 39: Latin America Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)
Figure 40: Latin America Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 41: Latin America Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 42: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 43: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 44: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 45: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032
Figure 46: Mexico Market Value Proportion Analysis, 2022
Figure 47: Global Vs. Mexico Growth Comparison, 2022-2032
Figure 48: Mexico Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 49: Mexico Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 50: Mexico Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 51: Brazil Market Value Proportion Analysis, 2022
Figure 52: Global Vs. Brazil Growth Comparison, 2022-2032
Figure 53: Brazil Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 54: Brazil Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 55: Brazil Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 56: Argentina Market Value Proportion Analysis, 2022
Figure 57: Global Vs. Argentina Growth Comparison, 2022-2032
Figure 58: Argentina Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 59: Argentina Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 60: Argentina Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 61: Europe Alzheimer’s Therapeutics Market Split By Country, 2022 (E)
Figure 62: Europe Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)
Figure 63: Europe Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)
Figure 64: Europe Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)
Figure 65: Europe Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 66: Europe Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 67: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 68: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 69: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 70: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032
Figure 71: Germany Market Value Proportion Analysis, 2022
Figure 72: Global Vs. Germany Growth Comparison, 2022-2032
Figure 73: Germany Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 74: Germany Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 75: Germany Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 76: Italy Market Value Proportion Analysis, 2022
Figure 77: Global Vs. Italy Growth Comparison, 2022-2032
Figure 78: Italy Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 79: Italy Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 80: Italy Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 81: France Market Value Proportion Analysis, 2022
Figure 82: Global Vs. France Growth Comparison, 2022-2032
Figure 83: France Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 84: France Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 85: France Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 86: U.K. Market Value Proportion Analysis, 2022
Figure 87: Global Vs. U.K. Growth Comparison, 2022-2032
Figure 88: U.K. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 89: U.K. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 90: U.K. Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 91: Spain Market Value Proportion Analysis, 2022
Figure 92: Global Vs. Spain Growth Comparison, 2022-2032
Figure 93: Spain Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 94: Spain Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 95: Spain Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 96: BENELUX Market Value Proportion Analysis, 2022
Figure 97: Global Vs. BENELUX Growth Comparison, 2022-2032
Figure 98: BENELUX Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 99: BENELUX Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 100: BENELUX Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 101: Nordic Countries Market Value Proportion Analysis, 2022
Figure 102: Global Vs. Nordic Countries Growth Comparison, 2022-2032
Figure 103: Nordic Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 104: Nordic Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 105: Nordic Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 106: Russia Market Value Proportion Analysis, 2022
Figure 107: Global Vs. Russia Growth Comparison, 2022-2032
Figure 108: Russia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 109: Russia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 110: Russia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 111: East Asia Alzheimer’s Therapeutics Market Split By Country, 2022 (E)
Figure 112: East Asia Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)
Figure 113: East Asia Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)
Figure 114: East Asia Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)
Figure 115: East Asia Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 116: East Asia Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 117: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 118: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 119: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 120: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032
Figure 121: China Market Value Proportion Analysis, 2022
Figure 122: Global Vs. China Growth Comparison, 2022-2032
Figure 123: China Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 124: China Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 125: China Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 126: Japan Market Value Proportion Analysis, 2022
Figure 127: Global Vs. Japan Growth Comparison, 2022-2032
Figure 128: Japan Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 129: Japan Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 130: Japan Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 131: South Korea Market Value Proportion Analysis, 2022
Figure 132: Global Vs. South Korea Growth Comparison, 2022-2032
Figure 133: South Korea Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 134: South Korea Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 135: South Korea Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 136: South Asia Alzheimer’s Therapeutics Market Split By Country, 2022 (E)
Figure 137: South Asia Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)
Figure 138: South Asia Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)
Figure 139: South Asia Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)
Figure 140: South Asia Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 141: South Asia Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 142: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 143: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 144: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 145: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032
Figure 146: India Market Value Proportion Analysis, 2022
Figure 147: Global Vs. India Growth Comparison, 2022-2032
Figure 148: India Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 149: India Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 150: India Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 151: Thailand Market Value Proportion Analysis, 2022
Figure 152: Global Vs. Thailand Growth Comparison, 2022-2032
Figure 153: Thailand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 154: Thailand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 155: Thailand Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 156: Malaysia Market Value Proportion Analysis, 2022
Figure 157: Global Vs. Malaysia Growth Comparison, 2022-2032
Figure 158: Malaysia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 159: Malaysia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 160: Malaysia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 161: Philippines Market Value Proportion Analysis, 2022
Figure 162: Global Vs. Philippines Growth Comparison, 2022-2032
Figure 163: Philippines Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 164: Philippines Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 165: Philippines Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 166: Indonesia Market Value Proportion Analysis, 2022
Figure 167: Global Vs. Indonesia Growth Comparison, 2022-2032
Figure 168: Indonesia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 169: Indonesia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 170: Indonesia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 171: Vietnam Market Value Proportion Analysis, 2022
Figure 172: Global Vs. Vietnam Growth Comparison, 2022-2032
Figure 173: Vietnam Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 174: Vietnam Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 175: Vietnam Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 176: Oceania Alzheimer’s Therapeutics Market Split By Country, 2022 (E)
Figure 177: Oceania Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)
Figure 178: Oceania Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)
Figure 179: Oceania Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)
Figure 180: Oceania Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 181: Oceania Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 182: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 183: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 184: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 185: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032
Figure 186: Australia Market Value Proportion Analysis, 2022
Figure 187: Global Vs. Australia Growth Comparison, 2022-2032
Figure 188: Australia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 189: Australia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 190: Australia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 191: New Zealand Market Value Proportion Analysis, 2022
Figure 192: Global Vs. New Zealand Growth Comparison, 2022-2032
Figure 193: New Zealand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 194: New Zealand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 195: New Zealand Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 196: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Country, 2022 (E)
Figure 197: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)
Figure 198: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)
Figure 199: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)
Figure 200: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021
Figure 201: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032
Figure 202: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032
Figure 203: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032
Figure 204: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032
Figure 205: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032
Figure 206: GCC Countries Market Value Proportion Analysis, 2022
Figure 207: Global Vs. GCC Countries Growth Comparison, 2022-2032
Figure 208: GCC Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 209: GCC Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 210: GCC Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 211: Israel Market Value Proportion Analysis, 2022
Figure 212: Global Vs. Israel Growth Comparison, 2022-2032
Figure 213: Israel Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 214: Israel Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 215: Israel Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 216: Turkey Market Value Proportion Analysis, 2022
Figure 217: Global Vs. Turkey Growth Comparison, 2022-2032
Figure 218: Turkey Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 219: Turkey Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 220: Turkey Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 221: South Africa Market Value Proportion Analysis, 2022
Figure 222: Global Vs. South Africa Growth Comparison, 2022-2032
Figure 223: South Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 224: South Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 225: South Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 226: North Africa Market Value Proportion Analysis, 2022
Figure 227: Global Vs. North Africa Growth Comparison, 2022-2032
Figure 228: North Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032
Figure 229: North Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 230: North Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
